Clay Siegall, Scientist and Co-founder of Seattle Genetics announced Phase One Trial and Study of ADC, an antibody drug conjugate. The drug is referred to as SGN-CD352A and designed to treat patients whose MM (multiple myeloma) has rebelled or worsened against therapy treatment. It’s Seattle Genetics ninth clinical stage program to test and analyze ADC on patients who resist present therapy or relapse the cancerous disease. The Company is the leader of antibody drug conjugate development, with over 15 years of experience creating therapies for various cancers.
Richard Lechleider, senior vice president of Clinical Development at Seattle Genetics in a Business Wire press release, on January 5th, 2017 said more than 124,000 people is diagnosed with multiple myeloma yearly. In Phase One of the Clinical Stage Program, scientists and researchers will evaluate the safety and activity of ADC in adult patients only. The therapy drug will be administered every four weeks to approximately 75 relapsed or refractory patients at selected U.S. centers. The new investigational antibody drug is administered using Seattle Genetics ADC proprietary technology that treats blood cancers and tumors. ADC technology joins the aiming ability of monoclonal antibodies to deliver agents that kills cancer cells.
In 1998, Clay Siegall co-founded Seattle Genetics and serves as president, chief executive officer, and chairman. The University of Maryland and George Washington University graduate successfully earned his bachelor of science and doctoral degrees in zoology and genetics. As leader of Seattle Genetics, he accomplished raising over $1 billion in public and private funding, and developed 15 therapeutic drug patents. He headed the development of the company’s first antibody drug conjugate product, Adcetris, which is approved in 61 or more countries.
Clay Siegall received approval from the Federal Drug Administration of Adcetris, in 2011. He presently serves as the board of directors for organizations, including Washington Roundtable, Alder Biopharmaceuticals and Ultragenyx Pharmaceutical. Seattle Genetics is headquartered in Bothell, Washington and has an office located in Switzerland. The biotechnology company is in the process of enrolling up to 75 relapsed or refractory patients into the Phase One Clinical Stage Program.